2021 Form 10-K Financial Statement
#000156459021049235 Filed on September 28, 2021
Income Statement
| Concept | 2021 | 2020 Q2 | 2020 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $9.757M | $1.470M | $4.510M |
| YoY Change | 116.34% | -24.23% | -4.85% |
| % of Gross Profit | |||
| Research & Development | $27.91M | $1.300M | $3.630M |
| YoY Change | 668.84% | 35.42% | -0.87% |
| % of Gross Profit | |||
| Depreciation & Amortization | $30.00K | $0.00 | $10.00K |
| YoY Change | 200.0% | -100.0% | -50.0% |
| % of Gross Profit | |||
| Operating Expenses | $37.67M | $2.770M | $9.198M |
| YoY Change | 309.49% | -4.48% | 9.52% |
| Operating Profit | |||
| YoY Change | |||
| Interest Expense | $30.00K | $0.00 | $70.00K |
| YoY Change | -57.14% | -100.0% | -85.42% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$132.0K | $72.00K | |
| YoY Change | -283.33% | -79.44% | |
| Pretax Income | -$38.30M | -$3.820M | -$9.130M |
| YoY Change | 319.47% | 48.06% | 13.42% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$38.30M | -$3.820M | -$9.126M |
| YoY Change | 319.66% | 48.06% | 13.39% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$1.60 | -$0.87 | |
| Diluted Earnings Per Share | -$1.479M | -$334.2K | -$874.5K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 25.89M | 10.44M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 | 2020 Q2 | 2020 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $10.54M | $2.390M | $2.390M |
| YoY Change | 340.88% | -35.75% | -35.75% |
| Cash & Equivalents | $10.54M | $2.392M | $2.390M |
| Short-Term Investments | |||
| Other Short-Term Assets | $1.256M | $450.0K | $450.0K |
| YoY Change | 179.11% | 60.71% | 60.71% |
| Inventory | |||
| Prepaid Expenses | $365.0K | ||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $11.79M | $2.851M | $2.850M |
| YoY Change | 313.79% | -29.17% | -29.28% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $150.0K | $2.000K | |
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $1.600M | $80.00K | $80.00K |
| YoY Change | 1900.0% | ||
| Total Long-Term Assets | $1.750M | $87.00K | $90.00K |
| YoY Change | 1844.44% | 621.27% | 800.0% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $11.79M | $2.851M | $2.850M |
| Total Long-Term Assets | $1.750M | $87.00K | $90.00K |
| Total Assets | $13.54M | $2.938M | $2.940M |
| YoY Change | 360.65% | -27.23% | -27.23% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.219M | $2.010M | $2.010M |
| YoY Change | 10.4% | 15.52% | 15.52% |
| Accrued Expenses | |||
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.780M | $2.675M | $2.670M |
| YoY Change | 4.12% | 29.23% | 28.99% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $182.0K | ||
| YoY Change | |||
| Total Long-Term Liabilities | $182.0K | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.780M | $2.675M | $2.670M |
| Total Long-Term Liabilities | $182.0K | $0.00 | $0.00 |
| Total Liabilities | $2.962M | $2.675M | $2.670M |
| YoY Change | 10.94% | 29.24% | 28.99% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$69.72M | ||
| YoY Change | 15.09% | ||
| Common Stock | $65.16M | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $10.58M | $263.0K | $260.0K |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $13.54M | $2.938M | $2.940M |
| YoY Change | 360.65% | -27.23% | -27.23% |
Cashflow Statement
| Concept | 2021 | 2020 Q2 | 2020 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$38.30M | -$3.820M | -$9.126M |
| YoY Change | 319.66% | 48.06% | 13.39% |
| Depreciation, Depletion And Amortization | $30.00K | $0.00 | $10.00K |
| YoY Change | 200.0% | -100.0% | -50.0% |
| Cash From Operating Activities | -$18.86M | -$2.580M | -$7.928M |
| YoY Change | 137.89% | 41.76% | 25.3% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$8.000K | ||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $972.0K | ||
| YoY Change | |||
| Cash From Investing Activities | $964.0K | ||
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 26.04M | 0.000 | 6.601M |
| YoY Change | 294.5% | -100.0% | 62.02% |
| NET CHANGE | |||
| Cash From Operating Activities | -18.86M | -2.580M | -7.928M |
| Cash From Investing Activities | 964.0K | ||
| Cash From Financing Activities | 26.04M | 0.000 | 6.601M |
| Net Change In Cash | 8.145M | -2.580M | -1.327M |
| YoY Change | -713.79% | -265.38% | -41.11% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$18.86M | -$2.580M | -$7.928M |
| Capital Expenditures | -$8.000K | ||
| Free Cash Flow | -$18.85M | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2021 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
0 | |
| CY2020Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
664000 | |
| CY2021Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2780000 | |
| CY2020Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2675000 | |
| CY2021 | us-gaap |
Open Tax Year
OpenTaxYear
|
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 | |
| CY2021 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2021 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
0 | |
| CY2021 | ktra |
Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
|
P3Y | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
||
| CY2020Q2 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
||
| CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2021 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
||
| CY2020 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
||
| CY2021 | us-gaap |
Interest Paid Net
InterestPaidNet
|
||
| CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
||
| CY2021 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2021 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2021 | dei |
Entity File Number
EntityFileNumber
|
001-37823 | |
| CY2021 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
| CY2021 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
99-0360497 | |
| CY2021 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
12707 High Bluff Dr | |
| CY2021 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 200 | |
| CY2021 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
San Diego | |
| CY2021 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2021 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
92130 | |
| CY2021 | dei |
City Area Code
CityAreaCode
|
858 | |
| CY2021 | dei |
Local Phone Number
LocalPhoneNumber
|
350-4364 | |
| CY2021 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
| CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2392000 | |
| CY2020Q2 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
365000 | |
| CY2021Q2 | ktra |
Clinical Trial Deposit Current
ClinicalTrialDepositCurrent
|
500000 | |
| CY2021Q2 | ktra |
Clinical Trial Deposit Non Current
ClinicalTrialDepositNonCurrent
|
1600000 | |
| CY2021Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
150000 | |
| CY2020Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2000 | |
| CY2020Q2 | us-gaap |
Deferred Costs
DeferredCosts
|
85000 | |
| CY2020Q2 | us-gaap |
Assets
Assets
|
2938000 | |
| CY2020Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2011000 | |
| CY2020 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
75000 | |
| CY2020 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
72000 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9126000 | |
| CY2020 | ktra |
Issuance Of Shares And Warrants Net Of Issue Cost
IssuanceOfSharesAndWarrantsNetOfIssueCost
|
6583000 | |
| CY2020 | ktra |
Exercise Of Pre Funded Warrants For Cash
ExerciseOfPreFundedWarrantsForCash
|
26000 | |
| CY2020 | ktra |
Exercise Of Warrants For Cash
ExerciseOfWarrantsForCash
|
25000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
13000 | |
| CY2020 | us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
287000 | |
| CY2021Q2 | ktra |
Milestone Payment Liability
MilestonePaymentLiability
|
182000 | |
| CY2021Q2 | us-gaap |
Liabilities
Liabilities
|
2962000 | |
| CY2020Q2 | us-gaap |
Liabilities
Liabilities
|
2675000 | |
| CY2020Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
95000000 | |
| CY2020Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
11458000 | |
| CY2020Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
11000 | |
| CY2020Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
65148000 | |
| CY2021 | ktra |
Merger Costs
MergerCosts
|
500000 | |
| CY2021 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-12000 | |
| CY2020 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-3000 | |
| CY2021 | us-gaap |
Other Amortization Of Deferred Charges
OtherAmortizationOfDeferredCharges
|
94000 | |
| CY2021 | us-gaap |
Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
|
-26000 | |
| CY2021 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-132000 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-38298000 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9126000 | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-38298000 | |
| CY2021 | us-gaap |
Dividends Preferred Stock Stock
DividendsPreferredStockStock
|
3181000 | |
| CY2021 | us-gaap |
Dividends Preferred Stock Cash
DividendsPreferredStockCash
|
8000 | |
| CY2020 | us-gaap |
Dividends Preferred Stock Cash
DividendsPreferredStockCash
|
8000 | |
| CY2021 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
17000 | |
| CY2020 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
9000 | |
| CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-41504000 | |
| CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-9143000 | |
| CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.60 | |
| CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.87 | |
| CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25886000 | |
| CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
10444000 | |
| CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
1968000 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
207000 | |
| CY2021 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
-103000 | |
| CY2020 | us-gaap |
Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
|
339000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
495000 | |
| CY2020 | ktra |
Series Preferred Stock Dividends
SeriesPreferredStockDividends
|
-8000 | |
| CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-9126000 | |
| CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
263000 | |
| CY2021 | ktra |
Adgero Merger Value
AdgeroMergerValue
|
16725000 | |
| CY2021 | ktra |
Issuance Of Series C Preferred Stock
IssuanceOfSeriesCPreferredStock
|
25028000 | |
| CY2021 | ktra |
Series C Preferred Stock Issue Costs
SeriesCPreferredStockIssueCosts
|
-3455000 | |
| CY2021 | ktra |
Exercise Of Warrants For Cash
ExerciseOfWarrantsForCash
|
4404000 | |
| CY2021 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
77000 | |
| CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5276000 | |
| CY2021 | ktra |
Series Preferred Stock Dividends
SeriesPreferredStockDividends
|
-8000 | |
| CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-38298000 | |
| CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10581000 | |
| CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-38298000 | |
| CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-9126000 | |
| CY2021 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2000 | |
| CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
10000 | |
| CY2021 | us-gaap |
Depreciation
Depreciation
|
30000 | |
| CY2021 | ktra |
In Progress Research And Development Expense
InProgressResearchAndDevelopmentExpense
|
16094000 | |
| CY2021 | ktra |
Gain Loss From Change In Fair Value Of Milestone Liability
GainLossFromChangeInFairValueOfMilestoneLiability
|
6000 | |
| CY2021 | us-gaap |
Interest Expense
InterestExpense
|
30000 | |
| CY2021 | ktra |
Amortization Of Deferred Loan Costs
AmortizationOfDeferredLoanCosts
|
94000 | |
| CY2020 | ktra |
Issuance Of Stock For Services
IssuanceOfStockForServices
|
13000 | |
| CY2021 | ktra |
Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
|
569000 | |
| CY2020 | ktra |
Increase Decrease In Fair Value Of Warrants Issued For Services
IncreaseDecreaseInFairValueOfWarrantsIssuedForServices
|
193000 | |
| CY2021 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
5276000 | |
| CY2020 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
495000 | |
| CY2021 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
381000 | |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
59000 | |
| CY2021 | ktra |
Increase Decrease In Clinical Trial Deposits
IncreaseDecreaseInClinicalTrialDeposits
|
-2100000 | |
| CY2021 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-67000 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18860000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-7928000 | |
| CY2021 | us-gaap |
Cash Acquired From Acquisition
CashAcquiredFromAcquisition
|
969000 | |
| CY2021 | us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
8000 | |
| CY2021 | us-gaap |
Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
|
3000 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
964000 | |
| CY2021 | ktra |
Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
|
21598000 | |
| CY2020 | ktra |
Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
|
6583000 | |
| CY2021 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
4404000 | |
| CY2020 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
51000 | |
| CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
77000 | |
| CY2021 | us-gaap |
Proceeds From Construction Loans Payable
ProceedsFromConstructionLoansPayable
|
500000 | |
| CY2021 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
500000 | |
| CY2021 | us-gaap |
Interest Paid
InterestPaid
|
30000 | |
| CY2020 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
25000 | |
| CY2021 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
8000 | |
| CY2020 | us-gaap |
Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
|
8000 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
26041000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6601000 | |
| CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
8145000 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1327000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2392000 | |
| CY2021Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
10537000 | |
| CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2392000 | |
| CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
3719000 | |
| CY2021Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-111225000 | |
| CY2021 | ktra |
Milestone Payment Liability Addition
MilestonePaymentLiabilityAddition
|
188000 | |
| CY2021 | ktra |
Milestone Payment Liability Change In Fair Value Estimate
MilestonePaymentLiabilityChangeInFairValueEstimate
|
-6000 | |
| CY2021Q2 | ktra |
Milestone Payment Liability
MilestonePaymentLiability
|
182000 | |
| CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10537000 | |
| CY2021 | ktra |
Proceeds From Registered Direct Financing Subsequent
ProceedsFromRegisteredDirectFinancingSubsequent
|
13600000 | |
| CY2021 | ktra |
Substantial Doubt About Companys Ability To Continues Going Concern Period
SubstantialDoubtAboutCompanysAbilityToContinuesGoingConcernPeriod
|
P1Y | |
| CY2021 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of operations, corporate history, and going concern and management plans</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of operations</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Kintara Therapeutics, Inc. (the “Company”) is a clinical stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. </span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate history</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc. (“Adgero”) (note 3). In conjunction with the Adgero merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Inc.”), formerly a wholly-owned subsidiary of Adgero.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Going concern and management plans</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;"> </span> <span style="Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:Times New Roman;"> </span><span style="Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;">For the year ended June 30, 2021, the Company reported a loss of $38,298 and a negative cash flow from operations of $18,860. The Company had an accumulated deficit of $111,225 and had cash and cash equivalents of $10,537 as of June 30, 2021. The Company is in the clinical stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. Despite the receipt of approximately $13.6 million in net proceeds from a registered direct financing subsequent to June 30, 2021, in the near future, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these consolidated financial statements. </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to secure the necessary financing through the issue of new equity and/or the entering into strategic partnership arrangements but the </span>ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic. <span style="Background-color:#FFFFFF;">The Company may not be able to raise sufficient additional capital and may tailor its drug candidates </span></p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.</span></p> | |
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-38298000 | |
| CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18860000 | |
| CY2021 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, clinical trial accruals, deferred tax valuation allowance and assessment of going concern. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p> | |
| CY2021 | ktra |
In Progress Research And Development Expense
InProgressResearchAndDevelopmentExpense
|
16094000 | |
| CY2021 | us-gaap |
Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
|
three years | |
| CY2021Q2 | us-gaap |
Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
|
0 | |
| CY2021 | ktra |
Accruals For Research And Development Expenses And Clinical Trials Policytext Block
AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicytextBlock
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accruals for research and development expenses and clinical trials</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2021 and 2020, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.</p> | |
| CY2021 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| us-gaap |
Legal Fees
LegalFees
|
1554000 | ||
| CY2021 | us-gaap |
Legal Fees
LegalFees
|
500000 | |
| CY2020 | us-gaap |
Legal Fees
LegalFees
|
1054000 | |
| CY2021 | us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
16724000 | |
| CY2021Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
|
969000 | |
| CY2021Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
|
11000 | |
| CY2021Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
|
175000 | |
| CY2021Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
|
337000 | |
| CY2021Q2 | us-gaap |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
|
188000 | |
| CY2021Q2 | ktra |
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities In Process Research And Development
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesInProcessResearchAndDevelopment
|
16094000 | |
| CY2021 | us-gaap |
Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
|
300000 | |
| CY2021Q2 | us-gaap |
Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
|
240000 | |
| CY2021 | us-gaap |
Payments To Employees
PaymentsToEmployees
|
60000 | |
| CY2021 | ktra |
Patient Enrollment Milestones Payments
PatientEnrollmentMilestonesPayments
|
5430000 | |
| CY2021 | ktra |
Deposits Payments
DepositsPayments
|
2600000 | |
| CY2021 | ktra |
Deposit Payment Expensed
DepositPaymentExpensed
|
500000 | |
| CY2021 | ktra |
Remainder Of Deposits Payments Anticipated To Future Invoice
RemainderOfDepositsPaymentsAnticipatedToFutureInvoice
|
2100000 | |
| CY2021 | ktra |
Deposits Payments Anticipated Short Term
DepositsPaymentsAnticipatedShortTerm
|
500000 | |
| CY2021 | ktra |
Deposits Payments Anticipated Long Term
DepositsPaymentsAnticipatedLongTerm
|
1600000 | |
| CY2019Q2 | ktra |
Property Equipment And Intangibles Assets
PropertyEquipmentAndIntangiblesAssets
|
12000 | |
| CY2020 | ktra |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAndIntangiblesAssets
|
10000 | |
| CY2020Q2 | ktra |
Property Equipment And Intangibles Assets
PropertyEquipmentAndIntangiblesAssets
|
2000 | |
| CY2021 | ktra |
Property Equipment And Intangibles Assets Gross
PropertyEquipmentAndIntangiblesAssetsGross
|
182000 | |
| CY2021 | ktra |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAndIntangiblesAssets
|
32000 | |
| CY2021Q2 | ktra |
Property Equipment And Intangibles Assets
PropertyEquipmentAndIntangiblesAssets
|
150000 | |
| CY2021 | us-gaap |
Payments For Software
PaymentsForSoftware
|
80000 | |
| CY2020 | us-gaap |
Payments For Software
PaymentsForSoftware
|
80000 | |
| CY2021 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
2000 | |
| CY2020 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
10000 | |
| CY2021Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
561000 | |
| CY2020Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
664000 | |
| CY2019Q3 | ktra |
Underwritten Public Offering Description
UnderwrittenPublicOfferingDescription
|
the Company closed on the sale of (i) 4,895 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,763 shares of Common Stock (“2020 Investor Warrants”), including 800 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,013 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant. | |
| CY2020 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
13000 | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
|
280000 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.61 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
|
53000 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6392000 | |
| CY2021Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2532000 | |
| CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5276000 | |
| CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
495000 | |
| CY2020Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
0.98 | |
| CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
5074 | |
| CY2021 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
|
1.67 | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
2058 | |
| CY2021 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
|
1.52 | |
| CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
14 | |
| CY2021 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice
|
1.42 | |
| CY2021Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
3860 | |
| CY2021Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
1.60 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2019Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
85 | |
| CY2019Q2 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice
|
11.35 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1291 | |
| CY2020 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice
|
0.63 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
500 | |
| CY2020 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice
|
1.87 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
18 | |
| CY2020 | ktra |
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice
|
0.61 | |
| CY2020Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
858 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
20148000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
11871000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
155000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
|
18000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
|
18000 | |
| CY2021Q2 | ktra |
Deferred Tax Assets Financing Cost
DeferredTaxAssetsFinancingCost
|
326000 | |
| CY2020Q2 | ktra |
Deferred Tax Assets Financing Cost
DeferredTaxAssetsFinancingCost
|
221000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
761000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
604000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
665000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
534000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
22073000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
13248000 | |
| CY2021Q2 | ktra |
Deferred Tax Liabilities Scientific Research And Development
DeferredTaxLiabilitiesScientificResearchAndDevelopment
|
110000 | |
| CY2020Q2 | ktra |
Deferred Tax Liabilities Scientific Research And Development
DeferredTaxLiabilitiesScientificResearchAndDevelopment
|
88000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
21963000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
13160000 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
21963000 | |
| CY2020Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
13160000 | |
| CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
8803000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1381000 | |
| CY2021 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | |
| CY2021Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
|
20400000 | |
| CY2021 | ktra |
Percentage Of Taxable Income Limitation On No Ls
PercentageOfTaxableIncomeLimitationOnNOLs
|
0.80 | |
| CY2021 | us-gaap |
Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
|
expire between 2031 and 2040 | |
| CY2021 | ktra |
Minimum Cumulative Percentage Of Change In Ownership As Condition To Offset Taxable Income Or Tax
MinimumCumulativePercentageOfChangeInOwnershipAsConditionToOffsetTaxableIncomeOrTax
|
0.50 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-8015000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1916000 | |
| CY2021 | ktra |
Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
|
4506000 | |
| CY2020 | ktra |
Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
|
142000 | |
| CY2021 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-551000 | |
| CY2020 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
-239000 | |
| CY2021 | ktra |
Income Tax Reconciliation Effect Of Foreign Exchange Rates
IncomeTaxReconciliationEffectOfForeignExchangeRates
|
-954000 | |
| CY2020 | ktra |
Income Tax Reconciliation Effect Of Foreign Exchange Rates
IncomeTaxReconciliationEffectOfForeignExchangeRates
|
347000 | |
| CY2021 | ktra |
Income Tax Reconciliation Non Capital Losses Acquired
IncomeTaxReconciliationNonCapitalLossesAcquired
|
-4114000 | |
| CY2021 | ktra |
Income Tax Reconciliation Nondeductible Expense Benefit Research And Development
IncomeTaxReconciliationNondeductibleExpenseBenefitResearchAndDevelopment
|
97000 | |
| CY2020 | ktra |
Income Tax Reconciliation Nondeductible Expense Benefit Research And Development
IncomeTaxReconciliationNondeductibleExpenseBenefitResearchAndDevelopment
|
-38000 | |
| CY2021 | ktra |
Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns
IncomeTaxReconciliationAdjustmentToPriorYearSProvisionVersusStatutoryTaxReturns
|
228000 | |
| CY2020 | ktra |
Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns
IncomeTaxReconciliationAdjustmentToPriorYearSProvisionVersusStatutoryTaxReturns
|
323000 | |
| CY2021 | ktra |
Manufacturing And Clinical Study Management Related Cost
ManufacturingAndClinicalStudyManagementRelatedCost
|
10049000 | |
| CY2021 | ktra |
Clinical Development Research Deposits
ClinicalDevelopmentResearchDeposits
|
2310000 | |
| CY2021 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
40000 | |
| CY2020 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
40000 | |
| CY2021 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
17000 | |
| CY2020 | us-gaap |
Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
|
9000 | |
| CY2021 | us-gaap |
Dividends Preferred Stock Stock
DividendsPreferredStockStock
|
3181000 | |
| CY2021 | ktra |
Non Cash Issue Costs
NonCashIssueCosts
|
3287000 | |
| CY2020 | ktra |
Non Cash Issue Costs
NonCashIssueCosts
|
182000 | |
| CY2020 | ktra |
Deferred Costs In Accounts Payable
DeferredCostsInAccountsPayable
|
60000 | |
| CY2020 | ktra |
Warrants Issued As Deferred Costs
WarrantsIssuedAsDeferredCosts
|
94000 | |
| CY2021 | ktra |
Conversion Of Series B Preferred Stock Shares To Common Stock
ConversionOfSeriesBPreferredStockSharesToCommonStock
|
4525000 | |
| CY2020 | ktra |
Conversion Of Series B Preferred Stock Shares To Common Stock
ConversionOfSeriesBPreferredStockSharesToCommonStock
|
174000 | |
| CY2021 | ktra |
Conversion Of Series C Preferred Stock To Common Stock
ConversionOfSeriesCPreferredStockToCommonStock
|
3713000 | |
| CY2021 | us-gaap |
Concentration Risk Credit Risk Financial Instrument Maximum Exposure
ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
|
8000 | |
| CY2021 | ktra |
Concentration Risk Credit Risk Uninsured Amount Of Cash
ConcentrationRiskCreditRiskUninsuredAmountOfCash
|
9909000 | |
| CY2021Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10537000 | |
| CY2021Q2 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
628000 | |
| CY2021Q2 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
9909000 |
